Peripheral Arterial Disease News and Research

RSS

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS).

15 Oct 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

Journal of Endovascular Therapy publishes latest update to TASC II guidelines

The Journal of Endovascular Therapy, official publication of the INTERNATIONAL SOCIETY OF ENDOVASCULAR SPECIALISTS (ISES), announces that is it today publishing the latest update of the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), an internationally recognized set of guidelines for the management of patients with peripheral arterial disease (PAD).

5 Aug 2015

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16").

3 Aug 2015

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

3 Jun 2015

Novel method predicts risk of sudden cardiac death in hemodialysis patients

A new test has been developed to predict sudden cardiac death in hemodialysis patients in whom such forecasts were previously impossible. The novel method was presented at ICNC 12 by Dr Akiyoshi Hashimoto, a cardiologist at Sapporo Medical University in Japan. The test uses a combination of nuclear medicine, C-reactive protein and electrocardiogram (ECG).

5 May 2015

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel.

28 Apr 2015

Two radiologists win Society of Interventional Radiology Foundation Leaders in Innovation Award

Two visionaries of interventional radiology were recently awarded the Society of Interventional Radiology Foundation Leaders in Innovation Award. The awards, to Lindsay Machan, M.D., FSIR, an interventional radiologist at Vancouver Hospital, British Columbia, and Kieran J. Murphy, M.D., FSIR, an interventional radiologist at the University of Toronto, both in Canada, were announced March 4 during the society's Annual Scientific Meeting in Atlanta.

13 Apr 2015

Novel technology could improve diagnosis of peripheral arterial disease

Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes.

26 Feb 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®.

From COOK MEDICAL INC. 4 Feb 2015

Rose Medical Center becomes first hospital in Colorado to perform new procedure for PAD patients

Rose Medical Center is the first hospital in Colorado to perform a new and innovative procedure for patients with peripheral arterial disease (PAD). Utilizing the Lutonix 035 Drug Coated Balloon PTA Catheter, surgeons are able to perform a balloon angioplasty in patients with PAD using a special drug-coated balloon (DCB) that delivers a small amount of medication to the inside walls of the diseased portion of the artery.

12 Nov 2014

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

The Mount Sinai Hospital is first in the United States to use the first and only FDA-approved, drug-coated balloon to open blocked arteries in the leg.

15 Oct 2014

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

14 Oct 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.

19 Aug 2014

Drug-eluting peripheral stent from Cook Medical selected as a top 10 game-changing health technology for 2014

As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver® PTX® drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada.

From COOK MEDICAL INC. 24 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Cordis launches SABER Catheter for treatment of patients with Peripheral Arterial Disease

Cordis Corporation announced today the launch of its SABER PTA Dilatation Catheter ("SABER Catheter") for the treatment of patients with Peripheral Arterial Disease (PAD).

1 Jul 2014

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It's the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA).

From COOK MEDICAL INC. 5 Jun 2014

Zilver® PTX® drug-eluting stent from Cook Medical receives positive one-year follow-up results

One-year follow-up data from 907 Japanese patients who received the Zilver® PTX® drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stent’s performance in real-world patient use, was presented at the 2014 Euro PCR meeting.

From COOK MEDICAL INC. 29 May 2014